Medeor Therapeutics
Medeor Therapeutics is dedicated to improving transplant outcomes by developing innovative immunotherapies that enable long-lasting immune tolerance, potentially eliminating the need for lifelong immunosuppressant drugs. With a platform based on 20 years of research from Stanford University, the company focuses on creating cellular therapies that induce mixed chimerism, promoting immune acceptance of transplanted organs and treating hematological diseases. Currently in Phase 3 clinical trials, Medeor aims to transform transplant medicine and address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Medeor Therapeutics
South San Francisco, California, United States, North America
Products
Cellular immunotherapy candidate for induction of transplant tolerance (HLA-matched living-donor kidney)
A patient-specific donor/recipient cellular product designed to induce mixed chimerism and donor-specific immune tolerance following a single-dose infusion; developed through Phase 3 for HLA-matched living-donor kidney transplant recipients.
Cellular immunotherapy candidates for mismatched and delayed-tolerance transplant protocols
Pipeline candidates developed to induce mixed chimerism in HLA-mismatched living-donor kidney transplants and delayed-tolerance protocols (Phase 2), using similar donor/recipient cell approaches.
Hematology program candidates (including sickle cell disease IND-stage program)
Programs applying mixed-chimerism approaches to hematologic and potentially oncologic indications; includes at least one IND-stage program for sickle cell disease.
Cellular immunotherapy candidate for induction of transplant tolerance (HLA-matched living-donor kidney)
A patient-specific donor/recipient cellular product designed to induce mixed chimerism and donor-specific immune tolerance following a single-dose infusion; developed through Phase 3 for HLA-matched living-donor kidney transplant recipients.
Cellular immunotherapy candidates for mismatched and delayed-tolerance transplant protocols
Pipeline candidates developed to induce mixed chimerism in HLA-mismatched living-donor kidney transplants and delayed-tolerance protocols (Phase 2), using similar donor/recipient cell approaches.
Hematology program candidates (including sickle cell disease IND-stage program)
Programs applying mixed-chimerism approaches to hematologic and potentially oncologic indications; includes at least one IND-stage program for sickle cell disease.
Services
Clinical development of transplant tolerance therapies
End-to-end clinical development services for cell-based transplant tolerance programs, including protocol design, trial execution, outcomes monitoring, and regulatory engagement.
Patient and physician informational support
Provision of educational materials and resources for patients and treating physicians about investigational cell-therapy options and clinical-trial participation.
Clinical development of transplant tolerance therapies
End-to-end clinical development services for cell-based transplant tolerance programs, including protocol design, trial execution, outcomes monitoring, and regulatory engagement.
Patient and physician informational support
Provision of educational materials and resources for patients and treating physicians about investigational cell-therapy options and clinical-trial participation.
Expertise Areas
- Clinical trial management for transplant immunotherapies (Phase 1–3)
- Cellular immunotherapy development
- Mixed chimerism and transplant tolerance
- Transplant immunology and conditioning protocols
Key Technologies
- Mixed-chimerism cell therapy
- Hematopoietic stem/progenitor cell (CD34+) transplantation
- T-cell (CD3+) based immunomodulation
- Single-dose donor/recipient cell infusion